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Abstract
Even  if  Chronic  lymphocytic  leukemia  (CLL)
responsiveness to cytoreductive treatment, about 20% of the patients, so called “poor
patients,  show  an  aggressive  course  and  die  within  a  few  years  despite  early  intensive 
therapies.  Criteria  for  poor-risk  d
Transplantation  (EBMT)  CLL  Transplant  Consensus  are:  purine  analogue  refractoriness, 
early  relapse  after  purine  analogue  combination  therapy,  CLL  with  p53  lesion  requiring 
treatment.
Allogeneic  transplant has  potential  curative  role  in CLL,  however burden with  very  high 
transplant related mortality (TRM) rates of 38
term  morbidity  and  mortality  of  allogeneic  stem  cell  transplantation  (SCT)  has  been  the 
introduction of non-myeloablative or reduced intensity conditioning (RIC) regimens to allow 
engraftment of allogeneic stem cells. There is no doubt that the crucial therapeutic principle 
of allo-SCT in CLL is graft versus leukemia (GVL) activity.
The  major  complications  of  allogeneic  SCT  in CLL  are:  chronic  graft
(GVHD)  affecting  quality  of  life,  high  graft  rejection  and  infection  rates  correlated  with 
preexisting immunosuppression. Disease relapse remains the major cause of failure after RIC 
allo-HCT in CLL patients.
Sensitive minimal residual disease (MRD) quantification has strong prognostic impact after 
transplant. 
Introducion: Chronic lymphocytic leukemia (CLL) 
is the most common adult leukaemia in the Western 
World
1 and has long been  considered an indolent 
disease affecting elderly patients, with a median age 
at diagnosis of approximately 72 years. 
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Even  if  Chronic  lymphocytic  leukemia  (CLL) often  has  an  indolent  behavior  with  good 
responsiveness to cytoreductive treatment, about 20% of the patients, so called “poor
patients,  show  an  aggressive  course  and  die  within  a  few  years  despite  early  intensive 
risk  disease  according  to  the  European  Bone  Marrow 
Transplantation  (EBMT)  CLL  Transplant  Consensus are:  purine  analogue  refractoriness, 
early  relapse  after  purine  analogue  combination  therapy,  CLL  with  p53  lesion  requiring 
tential  curative  role  in CLL,  however burden with  very  high 
transplant related mortality (TRM) rates of 38–50%. A major advance in reducing the short
term  morbidity  and  mortality  of  allogeneic  stem  cell  transplantation  (SCT)  has  been  the 
myeloablative or reduced intensity conditioning (RIC) regimens to allow 
engraftment of allogeneic stem cells. There is no doubt that the crucial therapeutic principle 
SCT in CLL is graft versus leukemia (GVL) activity.
allogeneic  SCT in  CLL  are:  chronic  graft-versus
(GVHD)  affecting  quality  of  life,  high  graft  rejection  and  infection  rates  correlated  with 
preexisting immunosuppression. Disease relapse remains the major cause of failure after RIC 
Sensitive minimal residual disease (MRD) quantification has strong prognostic impact after 
Chronic lymphocytic leukemia (CLL) 
most common adult leukaemia in the Western 
and has long been  considered  an indolent 
disease affecting elderly patients, with a median age 
at diagnosis of approximately 72 years. 
In  parallel  with  improvements  in  treatment 
outcome, recent advances in the understanding of 
CLL biology have allowed us to identify selected 
subgroups  of  patients  with  adverse  characteristics 
such  as  chromosomal  abnormalities,
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often  has  an  indolent  behavior  with  good 
responsiveness to cytoreductive treatment, about 20% of the patients, so called “poor-risk” 
patients,  show  an  aggressive  course  and  die  within  a  few  years  despite  early  intensive 
isease  according  to  the  European  Bone  Marrow 
Transplantation  (EBMT)  CLL  Transplant  Consensus  are:  purine  analogue  refractoriness, 
early  relapse  after  purine  analogue  combination  therapy,  CLL  with  p53  lesion  requiring 
tential  curative  role  in CLL, however  burden with  very  high 
A major advance in reducing the short-
term  morbidity  and  mortality  of  allogeneic  stem  cell  transplantation  (SCT)  has  been  the 
myeloablative or reduced intensity conditioning (RIC) regimens to allow 
engraftment of allogeneic stem cells. There is no doubt that the crucial therapeutic principle 
versus-host-disease 
(GVHD)  affecting  quality  of  life,  high  graft  rejection  and  infection  rates  correlated  with 
preexisting immunosuppression. Disease relapse remains the major cause of failure after RIC 
Sensitive minimal residual disease (MRD) quantification has strong prognostic impact after 
In  parallel  with  improvements  in  treatment 
the understanding  of 
CLL biology have allowed us to identify selected 
subgroups  of  patients  with  adverse  characteristics 
such  as  chromosomal  abnormalities,
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immunoglobulin  heavy  chain  (IgVh)  gene 
mutational  status,
3 zeta  associated  protein  70 
(ZAP70)
4 and  CD38  expression,
5 some  of  whom 
have projected survival as short as 3 years.
Even  if  CLL  often  has  an  indolent  behavior 
with  good  responsiveness  to  cytoreductive 
treatment,  about  20%  of  the  patients  who  need 
treatment show an aggressive course and die within 
a few years of diagnosis despite early institution of 
intensive  therapies.  These  so  called  “poor-risk” 
patients are characterized by preexisting or rapidly 
developing  resistance  to  conventional 
chemotherapy, including modern purine analogue-
antibody  combination  regimens
6,7    with  a  dismal 
survival of less than 12 months.
8,9
Although  alemtuzumab,  lenalidomide,  and 
flavopiridol,  show  promising  activity  in  some 
patients  with  poor-risk  CLL,  none  of  these 
compounds seem to be able to change the  natural 
course of poor-risk CLL.
10-14
Transplant in CLL: Myeloablative allogeneic SCT 
has several theoretical advantages over autologous 
SCT. Firstly, any potential tumor contamination of 
the stem cell product is eliminated  even if  new 
data are emerging about the potential possibility of 
CLL  transmission  by    unrecognized  CLL/MBL 
(Monoclonal B Lymphocytosis) donor.
15 Secondly, 
there is the potential for the graft versus leukaemia 
(GVL)  effect  to  eliminate  chemotherapy-resistant 
leukaemia cells by immune mechanisms. Moreover, 
in contradistinction with the results of  autologous 
SCT  plateaus  in  the  survival  curves  emerge  1–2 
years following allogeneic transplantation.
The  enthusiasm  for  myeloablative  allogeneic 
SCT  in  CLL,  using  either  related  or  unrelated 
donors,  is  however  tempered  by  registry  reports 
showing  very  high TRM rates of 38–50%: these 
published  data  showed  that  approximately  two-
thirds  of  allotransplanted  CLL  patients  will 
succumb either to TRM or to recurrent disease, and 
approximately  one-third  will  be  cured  of  their 
disease.
16,17 Moreover patients with chemosensitive 
disease  have  significantly  better  outcomes  than 
patients with refractory disease, suggesting that an 
earlier application of  allogeneic  SCT may  further 
improve transplantation outcomes.
A  major  advance  in  reducing  the  short-term 
morbidity and mortality of allogeneic SCT has been 
the  introduction  of  non-myeloablative  or  reduced 
intensity  conditioning  (RIC)  regimens  to  allow 
engraftment  of  allogeneic  stem  cells.  So  the  RIC 
regimens were developed in the 1990s to allow allo-
SCT  in  older  patients  or  younger  patients  with 
comorbidities  and  the  total  number  of  allogeneic 
transplantations  for  CLL  patients  in  Europe,  has 
almost treble in the last 7 years. In the last decade, 
many  reports,  which  enrolled  primarily  patients 
with  chemorefractory  end-stage  disease,  have 
stressed the potential curative role of RIC allo-SCT 
in CLL.
There is  no  doubt  that  the  crucial  therapeutic 
principle of allo-SCT in CLL is GVL activity. This 
evidence  derives  from  some interesting 
observations such as: decreasing relapse incidence 
over  time  even  in  RIC  alloSCT,  in  contrast  to 
autologous  SCT  or  other  intensive  therapies,
16-22
achievement  of  durable  clinical  and  molecular 
responses  due  to  antitumor  activity,23 reduced 
relapse rates in patients with chronic graft-versus-
host  disease  (GVHD),
20,24 increased  relapse  rates 
associated  with  T  cell–depleted  grafts
25,26    and 
efficacy of  donor lymphocyte infusions (DLIs) in 
the post-transplant relapse.
25,19,27
Multiple  single-center  phase  2  studies  have 
evaluated  several  different  RIC  regimens  with 
different  myeloablative  and  immunoablative 
potential (Table 1).
Ritgen  et  al  demonstrated  that  in  the  majority of 
cases  achievement  of  minimal  residual  disease 
(MRD)  negativity  was  clearly  linked  to  immune 
intervention,  such  as  tapering  of 
immunosuppression or donor lymphocyte infusions 
that  lead  to  develop  chronic  GVHD,  also  he 
suggests that a “GVL escape” mechanism might be 
acquired  during  the  post-transplantation  course 
probably caused by survival of clonogenic cells at 
“GVL  sanctuary”  sites.
23 Farina  et  al  confirmed 
GVL  activity  in  patients  in  clinical  complete 
response (CR) after RIC alloSCT showing delayed 
clearance or decrease of MRD levels upon chronic 
GVHD in clinical CR.
24 Both studies also detected 
that  MRD  negativity  1  year  post  transplant  was 
durable  over  the  entire  follow-up  period  in  more 
than 90% of patients and predictive for the virtual 
absence  of  clinical  relapse.  In  conclusion,  MRD 
kinetics studies consistently indicate that permanent 
MRD  negativity  after  alloSCT  for  CLL  can  be 
reached  in  the  context  of  chronic  GVHD  and/or 
immunomodulating  intervention.  Both  the 
durability of MRD remission and its sensitivity to
immunomodulation  strongly  suggest  that  GVL  is 
effective in CLL.
Ex-vivo  and  in-vivo  T-cell  depletion  are 
effective  means  of  preventing  acute  and  chronic 
GVHD  after  alloSCT.  In  CLL,  however,  T-cell 
depletion has been associated with increased relapse 
and rejection rates.
26-28 Now-a-day, considering the 
scanty data, the role of this type of transplantation 
in CLL is controversial.Medit J Hemat Infect Dis 2010; 2(2): Open Journal System 3
Table 1: RIC allogeneic SCT for CLL
n Total 
patients
Age 
Year 
(range)
Prior 
Regimens 
(median)
Chemo-
Refractory
Prior 
Auto-
SCT
Donor TRM
GVHD 
Acute 
(Grade 
II-IV)
GVHD 
Chronic 
(extensive)
Survival Referenc
e
30 30
50
3 47% n.d.
50% 
related 13%
56% 21%
OS 72% 
2 yr
Schetelig 
et al
(12–63) 50% 
unrelated (overall) PFS 
67% 2003
77 77
54
3 33% 10 81% 
related
18%
34% 58%
OS 72% 
2 yr
Dreger et 
al
(30–66) (12m) PFS 
56% 2003
46 46
53
5 57% 10
33% 
related 17%
34% 43%
OS 54% 
2 yr
Brown 
et al
(35–67) 67% 
unrelated (overall) PFS 
34% 2006
41 41
54
3 27% 11
58% 
related 5% 10%
33%
OS 51 2 
yr
Delgado 
et al
(37–67) 42% 
unrelated (100 d) (III-IV) PFS 
45% 2006
39 39
57
3 n.d. n.d.
90% 
related 26%
45% 58%
OS 48% 
4 yr
Khouri 
et al
(34–70) 10% 
unrelated (overall) PFS 
44% 2006
82 82
82
4 87% 4
63% 
related 25%
55%
49% 
related
OS 50% 
5 yr
Sorror 
et al
(42–72) 37% 
unrelated (overall) 53% 
unrelated
PFS 
45% 2008
11 11
57
4 45% 3
73% 
related 27%
18% 36%
OS 73% 
2,5 yr
Laurenti 
et al
(49-70) 27% 
unrelated (overall) PFS 
55% 2010
25 25
57
3 n.d. 6
88% 
related 13% 40% 60% OS 55% 
5 ys
Iori 
et al
(45-70) 12% 
unrelated (overall) (I-IV) (overall) PFS 
43%
2010 
(abs)
“Poor risk” patients: indications and Allo-SCT 
timing    in  CLL:  European  Bone  Marrow 
Transplant  (EBMT)  guidelines  have  now  been 
established outlining indications for SCT in CLL
29
(Table  1).  In  the  absence  of  prospective 
randomized trials, the Consensus recommendations 
were based on evidence of grade II or less. 
Criteria for poor-risk disease according to the 
EBMT  CLL  Transplant  Consensus  are:  purine 
analogue  refractoriness,  early  relapse  after  purine 
analogue combination therapy, and CLL with p53 
lesion requiring treatment.
However considering the recent improvements 
in CLL treatment outcome, now-a-day one should 
test  other  innovative  and  very  promising 
therapeutically  approach  before  giving  the 
indication  to  alloSCT,  such  as:  antibody-purine 
analogue  combination  regimens  as  first-line  or 
salvage  treatment,
30,31 combined  alemtuzumab 
therapies  useful in fludarabine refractory and 17p-
/p53 patients as showed by the German CLL Study 
Group (GCLLSG) CLL2H study,
12 and novel agent 
flavopiridol  and  lenalidomide  capable  to  achieve 
30%  to  40%  response  rate  when used  as  salvage 
therapy  in  fludarabine-refractory  or  del  17p-
CLL.
13,14 Moreover  these  approaches  may  be 
helpful to achieve remission, a basic prerequisite for 
successful alloSCT.
32
The  EBMT  guidelines  conclude  that  there  is 
evidence-based efficacy of allogeneic SCT in CLLMedit J Hemat Infect Dis 2010; 2(2): Open Journal System 4
Table 2: Criteria for poor-risk disease according to the EBMT CLL Transplant Consensus.
Allo-SCT is a reasonable treatment option in poor-risk CLL including:
– Fludarabine resistance - non-response or early relapse (< 12 months) after purine analogue-based therapy
– Relapse < 24 months after purine analogue combinations or auto-SCT (+ high-risk genetics)
– p53 mutation with treatment indication
Auto-SCT indicated in clinical trial only.
and  that  this  procedure  is  indicated  in  high-risk 
CLL patients. It should be stressed that none of the 
EBMT  categories  requires  assessment  of  biologic 
risk factors except for cytogenetics for detection of 
p53 deletions, who deserves allogeneic SCT in first 
response. Ongoing prospective clinical studies will 
determine the impact of biomarkers including IgVh 
mutational  status  and  other  cytogenetic 
abnormalities  in  identification  of  patients  at 
sufficiently high risk to deserve use of allogeneic 
SCT in first CR.
Another  crucial  point  in  the  allogeneic 
transplant is a better selection of patient, as recently 
suggested  by  Sorror.
21 The  FHCRC  analysis 
revealed  that  comorbidities  were  more  important 
than  CLL-related  variables  for  predicting 
progression free survival (PFS) and overall survival 
(OS).
21 Another  risk  factor  for  non-relapse-
mortality  (NRM),  usually  correlated  with  the 
presence  of  comorbidities,  is refractory  disease at 
transplantation.
22 Thus, it would appear prudent to 
limit  allo-SCT to  fit  patients without  evidence of 
refractory disease.
In conclusion, allo-SCT is the only therapy with 
curative  potential  in  CLL  and,  in  contrast  to 
conventional treatment, with potential of providing 
long-term  disease  control  even  in  patients  with  a 
very unfavorable biological and clinical risk profile 
(Table 2). However in addition to the disease risk, 
patient-related  risk  factors,  such  as  age  and 
comorbidity,  have  to  be  considered  when  the 
decision about allo-SCT is made.
21,33
The  larger  RIC  prospective  trials  uniformly 
show  that  in  CLL  the  results  of  alloSCT  are 
considerably  impaired  if  the  disease  is  not  in 
remission  at  the  time  of  transplantation,  due  to 
nodal bulks and/or chemotherapy resistance. Thus, 
alloSCT  should  be  performed  before  CLL  has 
advanced to a status of complete refractoriness or 
large resistant tumor burden in order not to miss the 
“window of opportunity” for a successful outcome. 
In eligible patients, alloSCT should be considered 
as soon as the first and/or the third EBMT criterion 
is  met;  on  the  contrary,  the  optimum  timing  for 
alloSCT  in  patients  with  early  relapse  (within  2 
years)  after  purine  analogue  combination  therapy 
(second  EBMT  criterion)  needs  to  be  defined  by 
systematic studies.
On  the  other  hand,  RIC  allo-HCT  is  able  to 
mitigate the adverse prognosis conferred by purine
analog  resistance  and  unfavorable  genetics.  The 
EBMT  guidelines  identify  a  group  of  patients  in 
whom available therapies are unlikely to achieve a 
prolonged disease-free survival.
The  choice  of  Conditioning  regimen  and  stem 
cell source: Several prospective RIC studies with a 
combined  number  of  more  than  300  patients 
included on the basis of modern CLL-specific risk 
stratification give relatively  concordant  results.  In 
contrast,  the  experience  with  myeloablative 
conditioning  in  CLL  largely  relies  on  registry 
analyses  and  a  few  small  single-center  studies.
15-
18,34,28 Therefore,  RIC  rather  than  myeloablative 
conditioning represents the standard procedure for 
alloSCT in CLL. 
The  choice  of  RIC  alloSCT  as  the  standard 
procedure  rather  than  myeloablative  conditioning 
emerged  by  the  fact  that  the  crucial  therapeutic 
principle  of  allotransplantation  in  CLL  is  GVL 
activity. That evidence for superior direct cytotoxic 
activity of myeloablative conditioning over RIC is 
lacking, and also one should consider that CLL is 
an elderly disease.
35 At the same time  an increased 
incidence of relapse after RIC in comparison with 
myeloablative  conditioning  was  observed  in  a 
registry analysis, thus impaired disease control by 
RIC cannot be clearly ruled out.
20 Thus, according 
to the individual situation, the optimum choice of 
conditioning regimens may vary: in the presence of 
comorbidity and sensitive disease reduced-intensity 
regimens  appear  to  be  more  appropriate,  high-
intensity regimens might be preferable in younger 
patients  with  good  performance  status  but  poorly 
controlled disease.
36,29
A  matched  sibling  donor  should  be  preferred 
for  alloSCT  in  CLL  whenever  possible,  but  a 
matched  unrelated  donor  (MUD)  is  a  reasonable Medit J Hemat Infect Dis 2010; 2(2): Open Journal System 5
alternative  if  an  HLA-identical  sibling  is  not 
available.  In  fact  from  published  RIC  studies  in 
CLL, unfavorable effect of MUD respect to sibling 
donor did not significantly emerge.
19,21-22,27,37-38
Due to the median age of patients, experience 
with  haploidentical  transplant  and  cord  blood 
transplant is very scanty in CLL, and it is unlikely 
that  disease-specific  evidence  for  benefit  of  these 
procedures can ever be obtained. 
RIC allo-SCT was associated with a NRM of 
11%-34%,  a  PFS  of  34%-67%,  and  OS  of  48%-
72%  depending  on  the  conditioning  regimen  and 
follow-up. Long-term disease control was obtained 
in a substantial proportion of patients, particularly 
in those with chemosensitive and non-bulky disease 
at the time of transplantation. 
In the CLL3X trial of the German CLL Study 
Group (GCLLSG) and also in Schetelig data, poor 
risk  CLL  as  defined  by  purine-analogue 
refractoriness  or  presence  of  deletion  17p- had  a 
similar  outcome  to  patients  without  poor-risk 
characteristics  in  terms  of    PFS,  with  a  median 
follow up of 2 years.
19
The  outcome  of  82  patients  treated  at  the 
FHCRC  consortium  using  a  non-ablative 
conditioning  regimen  (fludarabine  and  low-dose 
total  body  irradiation)  was  recently  updated.
20
Eighty-seven  percent  of  patients  had  fludarabine 
refractory disease and 9% had del(17p). 
At 5 years after RIC allo transplant, the NRM 
and relapse rate were 23% and 38% respectively, 
which translated into a OS of 50% and PFS of 39%. 
Patients  with  bulky  lymphadenopathy  (>5  cm)  at 
the time of transplantation had a particularly poor 
outcome, with a 5-year relapse rate and PFS of 71% 
and 8% respectively. Extensive chronic GVHD was 
diagnosed  in  50%  of  patients,  but  it  resolved  in 
most of them.
21
A  retrospective  analysis  of  the  EBMT  on 
alloSCT in 44 patients with del 17p- CLL showed a 
3-year PFS of  37% with no event  occurring later 
than 3.5 years after transplant.
26
We  recently  reported  in  a  single  centre 
experience the efficacy and feasibility of RIC allo-
SCT in heavily pre-treated CLL patients, even if in 
a  small  number  of  patients  and  with  a  relatively 
short follow-up. In our series, 45% of patients were 
considered  “high-risk”  for  fludarabine-refractory 
disease or 17p deletion. At median follow-up of 20 
months  (range  12-44)  80%  of  them  are  alive, 
confirming literature data.
39
In  conclusion,  RIC  alloSCT  seems  to  be 
effective in poor-risk CLL, thereby overcoming the 
adverse  prognostic  impact  of  purine  analogue 
refractoriness  and  del  17p-.  However,  active, 
unresponsive  and  bulky  disease  at  the  time  of 
alloSCT still remains a predictor of an unfavorable 
outcome.
20-22,37
Complication  of  allogeneic  SCT  in  CLL  and 
post-transplant follow-up: The major determinant 
of long-term morbidity affecting quality of life after
alloSCT is chronic GVHD. Active chronic GVHD 
documented  a  significantly  reduced  long-term 
health  status  in  patients  allografted  for  various 
hematological malignancies.
40 Sorror et al. reported 
a 5-year cumulative incidence of extensive chronic 
GVHD of 49% for related and 53% for unrelated 
recipients.  However,  in  the  majority  of  affected 
patients  clinical  symptoms  of  chronic  GVHD 
resolved  over  time,  allowing  discontinuation  of 
systemic  therapeutic  immunosuppression  after  a 
median  of  25  months.
21 Transplant-related  long-
term  morbidity  after  alloSCT  for  CLL  can  be 
significant but is mainly restricted to those patients 
who have ongoing active chronic GVHD.
The  high  graft  rejection  rates  remain  a 
complication  either  of  myeloablative  or  non-
myeloablative transplant in CLL: it ranges between 
18%- 20% in conventional conditioning,
16,41 while 
in case of RIC regimen between 12-25% in T cell–
depleted  grafts  and  5-6%  in  unmanipulated 
grafts.
21,38,42 The  possible  explanations  for  this 
phenomenon  could  be  the  significant  marrow 
infiltration  in  CLL  patients  at  the  time  of 
transplantation,  inversely  correlated  with 
outcome
37,42 and the role played by host dendritic 
cells,  which  are  seriously  defective  in  CLL 
patients.
43
Another complication is represented by the high 
infection  rates  correlated  with  preexisting 
immunosuppression.  Infections  are  the  cause  of 
about 50% of all CLL-related deaths,
44-45 primarily 
in  fludarabine  and/or  alemtuzumab-refractory 
patients.
7,8 The  base  of  susceptibility  to 
development  infections  is the  immunosuppression 
before SCT both disease and therapy-related, rarely 
encountered  in  patients  with  other 
lymphoproliferative  disorders,  such  as  follicular 
lymphoma, whose main cause of  death is disease 
progression.
46 The multifactorial genesis should be 
secondary to hypogammaglobulinemia, defective T 
and  natural  killer  cell  function,  neutropenia,  and 
deficient complement activity.
47 Moreover in recent 
reports  the  risk  of  infections  has  been  clearly 
correlated  with  presence  of  GVHD
21,38,43,48 and 
refractory disease.
8,49
Disease  relapse  remains  the  major  cause  of 
failure after RIC allo-HCT in CLL patients. Early 
relapses are correlated with chemorefractory disease Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
at  the time  of  transplantation,  perhaps due to  the 
ineffectiveness of RIC regimens in contro
disease before the graft vesus CLL (GVCLL) effect 
can take place. 
Late  relapse  an  be  explaned  with  different 
mechanism  including:  CLL  clonal  evolutio
development  of  tolerance
25 and  the  survival  of 
tumor cells in “GVCLL sanctuary sites” bas
the negative  impact of  bulky lymphadenopathy at 
the  time  of  transplant  on  PFS,
21 inadequate  GVL 
effect  to  allow  a  complete  disease  eradication.  It 
should  be  noted  that  a  significant  percentage  of 
these late relapses occurred in lymph nodes in the 
absence  of  bone  marrow  or  peripheral  blood 
involvement,  or  even  in  patients  with  MRD 
negative status.
9,28,34,50-52
Sensitive MRD quantification can be studied in 
CLL by polymerase chain reaction (PCR) or flow 
cytometry-based  assays  and  has strong  prognostic 
impact  after  transplant.  The  generally  delayed 
decline of the MRD level and its close correlation 
with immune-relevant events strongly supports the 
assumption  that  GVL  activity  is  the  crucial 
contribution to tumor control in the allo
induced MRD negativity after allogeneic transplant 
is highly predictive of freedom from relapse.
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